The largest community of pharma leaders

CAP Demands Rationale from CDC on COVID-19 Testing Guidance

WASHINGTON–()–The College of American Pathologists (CAP) issued the following statement asking the Centers for Disease Control and Prevention (CDC) and the Department of Health and Human Services (HHS) to provide the scientific rationale when changing COVID-19 testing guidance:

The College of American Pathologists (CAP) applauds the American Medical Association’s recent statement CDC changes to COVID-19 testing guidance and likewise urges the Centers for Disease Control and Prevention (CDC) and the Department of Health and Human Services (HHS) to provide the scientific rationale when such guidance is issued now and in the future. Further, the CAP recognizes laboratory supply shortages are a serious issue as pathologists and laboratory professionals confront these shortages daily, however, the solution is not to halt testing of asymptomatic patients. Also, contacts of those infected with the virus should continue to be tested because of the threat of asymptomatic or pre-symptomatic transmission. The CAP looks forward to serving on the HHS National Testing Implementation Forum where we will address the key issues of supply chain shortcomings involved in testing and guiding optimal testing for various settings, such as those involving symptomatic and asymptomatic individuals.

About the College of American Pathologists

As the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. As a 501(c)(6) membership organization, the CAP is the only entity representing pathologists with unrestricted advocacy capability and a political action committee, PathPAC. For more information, visit to watch pathologists at work and see the stories of the patients who trust them with their care. Read the CAP Annual Report at


Recent Articles

AVROBIO to Present at Two Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene...

Global Neurofibromatosis Treatment Drugs Market to Surpass US$ 21,223.7 Million by 2027, Says Coherent Market Insights (CMI)

SEATTLE--(BUSINESS WIRE)-- #NeurofibromatosisTreatment--The Asia Pacific is expected to witness significant growth...

FDA Approves Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)

LONDON--(BUSINESS WIRE)--GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) today announced the US Food...

Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced today initiatives to bring attention to...

Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Receives ADLT Status for Envisia Genomic...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.